Improving cell based assays through viral vector technology - chances for target research and screening approaches

Thursday, April 4 2013
8:00 am – 10:00 am

This event was posted by Medicon Valley Alliance

Event Inquiries

Christel@sirion-biotech.de

Location: Cambridge Innovation Center, 1 Broadway, 5th floor, Cambridge, MA

For information and registration, please email:  Christel@sirion-biotech.de

7:30am-8:00am: Networking & Breakfast

8:00am-10:00am: 

Dr. Christian Thirion, Chief Technology Officer, Founder of Sirion-Biotech and Dr. Carl J. Christel, Manager, Sales at Sirion Biotech will discuss: 

Improving cell based assays through viral vector technology
- Chances for target research and screening approaches -

Requirements for cell based assays have induced a rapid development of novel cell models. To improve the effectiveness of target research and compound development the use of patient or stem cell-derived cell models is becoming increasingly important. SIRION Biotech specializes in viral vector technology and provides sophisticated cell modeling. 

Experience how viral vector technology can enable you to generate primary cell-based models with homogenous gene expression for high content screening or phenotypic analysis. Combined with a unique RNAi technology and expertise in cell culture SIRION Biotech offers access to in depth functional gene analysis

About SIRION Biotech

 Since 2006 SIRION Biotech has established itself as Europe's most comprehensive virus vector driven platform for genetic cell modeling. SIRION Biotech nurtures relations with clients in both academia and industry. It has proven its reliability through the successful completion of hundreds of projects. With clients in Europe, the USA and Japan, SIRION Biotech underlines its drive towards global recognition in the research community

Speakers Bio: 

Dr. Christian Thirion, Chief Technology Officer, Founder of Sirion-Biotech: Dr. Thirion holds a Ph.D. from the Munich Gene Center since 2004, where he conducted novel research on adenoviral vector technology and viral gene therapy. Since the founding of Sirion Biotech, Dr. Thirion has worked on cell modeling projects for more than 100 clients, shortening pre-clinical cycles in drug and related compound discovery. 

Dr. Carl J. Christel, Manager, Sales at Sirion Biotech: 

A true dual-citizen of American and German descent, Carl poses as a connection between Sirion’s German base headquarters and its US-task-force. He received his PhD at the TU Munich and completed
4 successful years at the University of Iowa, gaining a well based knowledge of cellular physiology in neuro- and cardiac biology. 

For information and registration, please email:  Christel@sirion-biotech.de

Share MassBio

 

 

MassBio Golf Classic

BioProcess

EvaluatePharma